Ian Clark has served as a member of the board of directors for Guardant Health since December 2016. Mr. Clark currently serves as Guardant’s Lead Independent Director and serves on the boards of directors of Corvus Pharmaceuticals, Inc., Shire Pharmaceuticals, Inc. and other privately-held companies, including Forty Seven, Inc. He is also a member of Forty Seven, Inc.’s audit committee, and he served on the board of directors and audit committee of Kite Pharma, Inc. from January 2017 to October 2017. He served as Chief Executive Officer of Genentech Inc., or Genentech, from January 2010 to December 2016. Prior to that, he was the Executive Vice President and Chief Marketing Officer of the Roche Group, or Roche, from April 2009 to December 2009. Prior to his time at Roche, Mr. Clark held several senior management positions at Genentech from January 2003 to March 2009, including Head of Global Product Strategy, Chief Marketing Officer, Senior Vice President, General Manager of BioOncology and Executive Vice President, Commercial Operations. Before joining Genentech, Mr. Clark spent 23 years in the biopharmaceutical industry in senior roles at Novartis International AG, Ivax Pharmaceuticals, Inc. and Sanofi S.A. in the United Kingdom, France and Eastern Europe. He started his career at G.D. Searle, LLC, a subsidiary of Monsanto Corporation, holding positions in sales and marketing. Mr. Clark received a B.S. degree in biology from South Hampton University.
What is Ian T. Clark's net worth?
The estimated net worth of Ian T. Clark is at least $99,224.65 as of June 29th, 2021. Mr. Clark owns 5,719 shares of Guardant Health stock worth more than $99,225 as of April 27th. This net worth estimate does not reflect any other assets that Mr. Clark may own. Learn More about Ian T. Clark's net worth.
How do I contact Ian T. Clark?
Has Ian T. Clark been buying or selling shares of Guardant Health?
Ian T. Clark has not been actively trading shares of Guardant Health over the course of the past ninety days. Most recently, Ian T. Clark sold 10,559 shares of the business's stock in a transaction on Tuesday, June 29th. The shares were sold at an average price of $130.00, for a transaction totalling $1,372,670.00. Following the completion of the sale, the director now directly owns 5,719 shares of the company's stock, valued at $743,470. Learn More on Ian T. Clark's trading history.
Who are Guardant Health's active insiders?
Are insiders buying or selling shares of Guardant Health?
During the last year, Guardant Health insiders bought shares 2 times. They purchased a total of 5,168 shares worth more than $136,480.85. During the last year, insiders at the sold shares 6 times. They sold a total of 10,991 shares worth more than $334,103.05. The most recent insider tranaction occured on March, 18th when insider Kumud Kalia bought 2,187 shares worth more than $38,972.34. Insiders at Guardant Health own 6.2% of the company.
Learn More about insider trades at Guardant Health. Information on this page was last updated on 3/18/2024.
